Ulcerative Colitis treatment at Guardian featured Harley Street IBS & Autoimmune Clinic addresses the underlying issues and not just the symptoms. Treatment is tailored to meet each patient’s unique needs. Patients report that this works better than a one size fits all approach.
In clinical trials, it was noted that natural treatment for Ulcerative Colitis provided beneficial effects to patients. In fact, those who received Natural Medicine, had a remission rate of 70% compared to 40% for pharmaceutical treatment.
What is Ulcerative Colitis?
Ulcerative Colitis (UC) is a very uncomfortable and debilitating condition. It affects the colon and rectum and usually involves just the innermost lining (mucosa) of the gut wall. It presents as continuous areas of inflammation and ulceration, with no segments of normal tissue. During the 20th Century, there was a significant increase in Ulcerative Colitis and it currently affects between 1 and 2 million people in the America. The figure for the UK has been estimated at 243 per 100,000. There is compelling evidence that environmental factors are far more important than genetic factors in Ulcerative Colitis. The most common symptoms of Ulcerative Colitis are abdominal pain and bloody diarrhoea. Patients also may experience anaemia, fatigue, weight loss, loss of appetite, rectal bleeding, skin lesions and joint pain.
About 50% of the people diagnosed with Ulcerative Colitis have mild symptoms. Others people suffer frequent fevers, bloody diarrhoea, nausea, and severe abdominal cramps. Ulcerative Colitis may also cause problems such as arthritis, inflammation of the eye, liver disease, and osteoporosis. This is a very stressful condition to have.
At Harley Street IBS & Autoimmune Clinic we treat the underlying cause and not just the symptoms. We see many patients, who come to us having relapsed after coming off steroids – in many cases several times – because the underlying issues fuelling the condition have not been diagnosed or treated.
Treatment at Harley Street IBS & Autoimmune Clinic includes addressing the imbalance of the gut flora (gut dybiosis), the immune dysregulation, the inflammation and the diet. Functional medicine tests are run in order to formulate the treatment plan and to meet the unique needs of each patient as everyone’s presentation of this condition is different and unique to them. This approach gets the best results – far better than a one-size-fits-all approach – according to our own clinical outcomes.
Patients usually progress well on natural treatment, providing they are diligent with their diet. We have a very experienced Nutritional Therapist on the team, who can help with your diet if you would like to make an appointment with her, once your underlying issues have been identified. It has usually taken many years for this condition to slowly develop and so it is not unusual for treatment to take some time to rebalance the body and help restore good health. However, some progress is usually seen early on in the treatment.
Khor B, Gardet A, Xavier RJ, et al. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307–17. [PMC free article] [PubMed]
Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology 2015;148:1087–106. [PMC free article] [PubMed]
Silva FA, Rodrigues BL, Ayrizono ML, et al. The immunological basis of inflammatory bowel disease. Gastroenterol Res Pract 2016;2016:2097274. [PMC free article] [PubMed]
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76. [PubMed] [Google Scholar]
Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–8. [PMC free article] [PubMed] [Google Scholar]
Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461–3. [PMC free article] [PubMed] [Google Scholar]
Jostins L, Ripke SW, Rinse K, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24. [PMC free article] [PubMed] [Google Scholar]
Frank DN, Amand ALS, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007;104:13780–5. [PMC free article] [PubMed] [Google Scholar]
LE Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–17. [PubMed] [Google Scholar]
Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285–96. [PubMed] [Google Scholar]
Read S, Malmstrom V, Powrie F, et al. T lymphocyteassociated antigen 4 plays an essential role in the function of CD25 (+)CD4 (+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295–302. [PMC free article] [PubMed] [Google Scholar]
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46.e42–54.e42. [PubMed] [Google Scholar]